Summary Points
|
![]() | ![]() |
Formats:
|
||||||||
Copyright : © 2008 Cheng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Strategies to Reduce Mortality from Bacterial Sepsis in Adults in Developing Countries * To whom correspondence should be addressed. E-mail:sharon/at/tropmedres.ac This article has been cited by other articles in PMC.Sepsis is a progressive injurious process resulting from a systemic inflammatory response to infection [1]. In developed countries, sepsis is an important cause of mortality: in the United States alone, up to 750,000 people annually suffer from severe sepsis—mostly bacterial in aetiology—of whom 29% may die [2,3]. Unfortunately, data on bacterial sepsis in developing countries are notably lacking, particularly in adults. Estimates of the burden of lower respiratory tract infections, meningitis, and “other infections”, of which a significant proportion are associated with severe sepsis, show that the majority of deaths and disability-adjusted life years lost occur in low-income countries (Figure 1 The standard of care varies significantly across lower- and middle-income developing countries, but published reports suggest that outcomes are poor even at major hospitals [5–10]. Melioidosis, a serious tropical infection caused by Burkholderia pseudomallei that often presents with sepsis, is endemic in a region containing both high- and low-income countries [11]. Outcomes vary significantly: the case fatality rate for melioidosis is higher in Thailand (40%–50%) than in Australia (10%–20%) [11–13], and the case-fatality rate for melioidosis with severe sepsis is approximately 50% in Singapore compared with 90% in a Thai clinical trial [14,15]. The burden of disease and case fatality of patients with melioidosis in less developed countries such as Cambodia and Myanmar are unknown. Although melioidosis is not common outside of southeast Asia, extrapolating this experience suggests that the outcomes from all-cause bacterial sepsis in underdeveloped regions are likely to be poor. The recently updated “Surviving Sepsis Campaign” guidelines have been widely disseminated in the developed world as a model of optimal sepsis management [16]. Although there has been some controversy regarding the recommendations and the development of the guidelines [17–19], most interventions based on improving early management of septic patients are less controversial. Crucially, most of the studies on which these recommendations are based were undertaken in the developed world and may not be applicable to the majority of the world's population who live in poorer regions. The purpose of this paper is to highlight the paucity of epidemiological or management data on bacterial sepsis in the developing world, discuss current management approaches to sepsis in adults, and examine how clinical sepsis management guidelines could be best adapted to provide improved care at low cost in under-resourced regions. We use the term “developing country” to refer to lower- or middle-income countries as defined by the World Bank [20].
Identification of Sepsis Interventions performed soon after diagnosis of sepsis in developed regions have been shown to improve survival [21,22], and in developing countries, interventions to identify and treat pneumonia in children reduce mortality [23]. Thus, prompt identification of sepsis in developing countries is an essential component of any management strategy. Most studies of infection have focused on specific diseases, but sepsis itself is a clinically recognisable syndrome despite its heterogeneous causes. From a practical standpoint, sepsis is largely a clinical diagnosis [24], and implementation of strategies to promote recognition of sepsis as a clinical syndrome should be feasible even in the most resource-challenged areas where supportive radiographic imaging or laboratory measurements are not available. Education of health care providers about sepsis is critical to enhance the early identification of sick patients and may help facilitate transfer to available health care facilities. Simple algorithms tailored to local medical capacities that comprise the basic components of sepsis, such as diagnosed or suspected infection and the systemic manifestations of infection, may be useful. Initial Treatment of Sepsis Volume resuscitation is a well-established initial therapy of sepsis. Many studies have demonstrated that tissue perfusion in sepsis is partly impaired by hypovolaemia [25,26], and patients may have substantial fluid deficits requiring 6–10 l within the first 24 hours [21,27]. Guidelines suggest that hypotensive patients should receive an initial challenge of 20 ml/kg or boluses of 500–1000 ml of crystalloid with ongoing monitoring of volume status [16,28,29]. Observational evidence suggests that aggressive fluid resuscitation was associated with decreased early mortality from typhoid with ileal perforation in a rural African hospital [30]. Although albumin is at least as effective as crystalloids for volume resuscitation in sepsis, the latter is cheaper and more widely available [31]. Judicious enteral fluid loading with standard oral rehydration solution has been used in other forms of hypovolaemia, but is as yet untested as a strategy in sepsis [32,33]. In severely compromised patients, oral fluids may be associated with a risk of pulmonary aspiration and are less likely to be effective with severe intravascular hypovolaemia. Invasively measured endpoints of fluid resuscitation have been defined [28], but clinical endpoints such as blood pressure and heart rate measurements, skin colour and capillary refill, mental status, or urinary output are the most feasible measures for monitoring in underdeveloped regions. Central venous access, where available, may be helpful for monitoring of central venous pressure and administration of vasopressors. Simpler non-invasive devices such as tissue perfusion monitors may be more practical but are not yet used widely [33]. Because septic shock is often characterised by inappropriate peripheral vasodilation, initiation of vasopressor therapies is indicated for persistent hypotension following fluid loading [16,34]. Although norepinephrine and (suprarenal dose) dopamine are accepted first-line agents [16,28], both may be associated with extravasation-related tissue necrosis if infused into a peripheral vein when central venous access is not possible. Accurate titration of intravenous vasopressors is also problematic in the absence of infusion pumps. Finally, non-invasive monitoring of blood pressure may be less accurate than intra-arterial blood pressure monitoring [16]. We have identified very few studies of non-intravenous vasopressor agents, such as oral midodrine [35], yet conceivably such therapies may play a role in sepsis management when intravenous medications are not feasible. Haemodynamic optimisation measures in the resuscitation of ill septic patients often require extensive nursing and medical resources. An invasive goal-directed haemodynamic optimisation therapy approach to early sepsis management, while effective, has proven challenging to implement even in large hospitals in the United States, and is not practical to consider in this form for health care facilities in most developing settings [21,36]. Nonetheless, in regions where basic sepsis therapies exist yet early management is suboptimal, enhanced care could be achieved with simple, clearly defined fluid resuscitation and blood pressure management protocols, incorporating clinical endpoints and non-invasive tools if available. In areas where paramedical staff are available, simply engaging an assistant to observe patient status may be a cost-effective substitute for electronic monitoring. In better staffed facilities, designation of a dedicated nurse for at least the initial resuscitation period may be beneficial. However, more studies are required to determine optimal fluid resuscitation strategies where invasive haemodynamic monitoring and fall-back therapies (such as mechanical ventilation and dialysis) may not be available. Antibiotic Regimens The timely and appropriate use of antibiotics in the early management period is associated with survival from sepsis and pneumonia [22,37]. A potential barrier to the formulation of an effective empiric antimicrobial regimen is that the spectrum of bacterial pathogens in the tropics is often diverse. In one study in Kenyan children, 16 individual pathogens, each of which accounted for less than 10% of cases, accounted for over a third of bacteraemias [38]. Similarly, in a study of adults in Nepal, no single pathogen accounted for more than 13% of patients where a pathogen was identified [39]. Many regions do not have access to diagnostic microbiology laboratories, so the causes of sepsis and their susceptibility profiles may not be known. The list of common bacterial pathogens may also show significant variation, even between neighbouring countries. An example of this is between the adjacent countries of Thailand and Laos. In northeast Thailand, common causes of community-acquired sepsis include Staphylococcus aureus, pneumococci and other streptococci, Escherichia coli and other Enterobacteriaceae, Pseudomonas spp., and B. pseudomallei [40], as well as leptospirosis, scrub typhus, and dengue [41]. In adjacent Vientiane, Laos, the commonest cause of community-acquired bacteraemia in one study was Salmonella enterica serovar typhi (50.9%), followed by S. aureus and E. coli [42]. Causes of hospital-acquired sepsis are also poorly characterised in resource-constrained settings where culture facilities are limited or absent, but lack of infection control infrastructure is likely to be associated with a significant burden of nosocomial sepsis. Because improved outcomes in sepsis management depend on early and appropriate antibiotic administration, it is critical that these issues be addressed in future epidemiological studies. The role of the clinical microbiology laboratory in developing countries has been discussed extensively elsewhere, and issues relating to problems with clinical misdiagnosis, poor use of existing resources, and quality assurance are well documented [43,44]. Possible solutions include the development of low-cost laboratories, or the intermittent use of mobile diagnostic “clinics” that can define the range of pathogens and their susceptibility patterns in a given area to inform a rational empiric prescribing policy. These data should be widely disseminated to clinicians within the region. Evidence for the impact on mortality of accurate diagnosis can be seen from mortality rates from melioidosis in northeast Thailand over time. The burden of melioidosis became apparent after diagnostic laboratories were introduced into this area in the early 1970s [45]. This led to the first clinical treatment trial that reported a reduction in mortality from 74% to 37% for patients with acute melioidosis treated with ceftazidime compared with the previous combination antibiotic therapy [46]. Similarly, recent clinical trials have been prompted by the recognition of emerging resistance in Salmonella typhi [47]. There are a number of concerns with respect to antibiotic therapy in developing regions. In many developing countries, antibiotics are not regulated and are freely available, particularly in urban areas. It is becoming widely appreciated that a significant proportion of patients in rural Asia will have taken antibiotics prior to presentation to hospital [48,49]. This has major implications both for antibiotic resistance and the sensitivity of diagnostic culture when the patient presents to hospital. The quality of antibiotics is a further consideration. Fake drugs are widespread in the tropics [50] and have been implicated in deaths from malaria. Furthermore, many antibiotics are stored at room temperature, but ambient temperatures may reach 40° C in the tropics.
Supportive and Adjunctive Therapeutic Agents Prophylaxis for deep venous thrombosis and for peptic “stress” ulcers can be readily implemented in many developing countries. Histamine blockers such as ranitidine are inexpensive and can be administered via nasogastric tube to intubated patients. Although some have argued that the incidence of venous thromboembolism is lower in populations of non-European origin [51–53], more recent evidence suggests that this may not be the case in post-operative and medical patients [54,55]. In the absence of studies in critically unwell patients with prolonged immobilisation, the use of subcutaneous unfractionated heparin seems warranted. Other interventions often used in the developed setting for patients with severe sepsis are renal replacement therapy and mechanical ventilation. Respiratory failure is a frequent complication of severe sepsis, and progression to acute lung injury is most commonly caused by sepsis [56,57]. In a trial of granulocyte colony stimulating factor in severe sepsis due to melioidosis in Thailand [15], 70% of patients required intubation and ventilation. Where available, mechanical ventilation of septic patients in developing countries is associated with extremely high mortality rates [6], and in some countries, patients with respiratory failure are ventilated by hand by relatives (A. C. Cheng, personal experience). Many ventilators in developing countries are simple devices that do not have minute ventilation alarms or allow for adjunct ventilator functions such as positive end-expiratory pressure. Sub-optimal ventilator care may lead to ventilator-associated pneumonia [58,59], and the lack of low-volume “lung-protective” strategies may be associated with poor outcomes from acute lung injury [60]. The reliance on non-invasive monitoring using peripheral oxygen saturation may reduce the ability to monitor the adequacy of ventilation. Although non-invasive positive-pressure ventilation is mainly used for respiratory failure in non-septic patients, it has been used successfully in developing countries [61,62], and strategies incorporating non-invasive positive-pressure ventilation should be evaluated further where invasive mechanical ventilation cannot be managed adequately. The cost of equipment and trained staff largely prohibits the use of renal replacement therapies in low-income settings, although they are used to a variable extent in rural regions of middle-income countries. In Vietnam, haemofiltration was more cost-effective than peritoneal dialysis in infection-related renal failure despite its significant cost [63]. This study primarily included patients with malaria, but such a study would be of significant interest in patients with sepsis in resource-constrained settings where haemofiltration is possible. In a study of severe sepsis in melioidosis, acute renal failure and acidosis were prominent on admission, suggesting that aggressive fluid resuscitation and/or renal replacement therapy would be potentially beneficial in this group [15]. There has been increasing awareness of the importance of acidosis and fluid and electrolyte imbalances in severe malaria, and despite differences in pathophysiology, such research may be relevant to severe bacterial sepsis [64,65]. There have been few trials of adjuvant therapies in developing countries, and results of studies may not be generalisable to this setting. For example, granulocyte colony stimulating factor appeared to be associated with significant benefit in treating melioidosis in Australia [13], but was not associated with a significant mortality benefit in Thailand in a clinical trial [15]. Conversely, high-dose steroids are not thought to be useful in severe sepsis generally, but may possibly have a specific application in severe typhoid [66–68]. Interventions that are of marginal benefit in developed countries, such as physiological dose steroid replacement [19,69] or intensive insulin therapy, are unlikely to be effective in developing countries in the absence of other standard intensive care interventions. The risk of adverse events, such as hypoglycaemia, associated with intensive insulin regimens are likely be greater in resource-poor settings, and the setting of less strict blood glucose targets may be warranted [16,18,70]. However, the safety and efficacy of such strategies require study. The effectiveness of activated protein C (drotrecogin alfa) has also been subject to intensive debate, but the cost of this therapy is prohibitive for most health care systems in developing countries [71,72]. Training Implicit in this discussion is the need for appropriately trained health care providers at the local level. Ideally, sepsis identification and management training should be integrated into general adult health care. Such a strategy is analogous to the World Health Organization's Integrated Management of Childhood Illness training course, which included severe infection, chronic diseases, and preventative measures for all levels of health workers including doctors, nurses, medical assistants, and literate paramedical workers at both a primary, and more recently, hospital level [73,74]. This course was integrated into a comprehensive strategy that also included measures to improve drug supply, health care infrastructure, and family behaviour in relation to sick children. Cost-Effectiveness The development of critical care services has significant resource implications for developing countries. We propose a stepwise approach based on income level, from extremely limited services in Africa and parts of southeast Asia, to more extended services in lower-middle-income countries such as Thailand and some South American countries (Table 1). Some evidence suggests that critical care services may be cost-effective even in poor countries, but such a decision needs to be made on a case-by-case basis [75]. We feel that with the current paucity of evidence regarding the effectiveness of potential interventions for severe sepsis, such decisions cannot currently be made. We further note that factors other than cost-effectiveness must be considered in priority setting in health care resource allocation, including equity, ethical, and political considerations [76]. However, where such services already exist, the challenge is to integrate these into the broader health care system to ensure access and to provide a cost-effective and sustainable staffing model [77]. Further research is required to define the most effective interventions for sepsis in developing countries, as well as evaluation and quality control programmes for existing services.
Prevention Few vaccines are available against most of the common causes of severe sepsis in the tropics, and many vaccines with known substantial efficacy against common diseases such as typhoid and pneumococcal disease are not generally available to developing countries because of cost. Other preventative measures may be useful for specific diseases. In a case-control study in northeast Thailand, the use of protective clothing reduced the incidence of leptospirosis [78], and protective footwear may also help prevent melioidosis, scrub typhus, snake bite, and physical injury. Although anecdotal reports suggested that farmers found protective footwear uncomfortable, particularly during the ploughing and planting seasons (V. Wuthiekanun, personal communication), it is possible that this obstacle could be overcome through a combination of education and the development of comfortable and practical clothing. Predictive modelling has proven to be a useful tool in malaria control [79], and similar techniques have been developed for a variety of other diseases such as cholera [80] and arboviruses [81]. Such tools might allow for targeting of public health interventions that may reduce exposure or disease transmission in specific populations. Conclusion The burden of sepsis is greatest in developing countries, and there is a need to translate modern management strategies for adults with severe sepsis to this context. The majority of studies of infectious diseases to date have been pathogen-specific, but efforts are required to define the epidemiology of all-cause sepsis in developing countries and to define the most cost-effective interventions that are sustainable in these countries. Principles of management may be adapted from current guidelines, particularly low-cost interventions targeted at early sepsis. Critical care services need to be considered in the context of competing priorities for resource allocation, but where they currently exist, standardised protocols need to be developed and evaluated to make the best use of available resources. Access to diagnostic facilities is fundamental to the care of the individual and to the development of logical and effective empiric prescribing regimens. Low-income countries rarely have access to diagnostic laboratories, and this is a major impediment to the improvement of care. Primary prevention is theoretically possible for a range of serious tropical infections, and studies are required to define acceptable measures and to validate their effectiveness. Acknowledgments We thank staff at the Sappasithiprasong Hospital and at the Mahidol-Oxford Tropical Medicine Research Unit for their support and advice. Footnotes Allen C. Cheng is with the Department of Medicine, University of Melbourne, and the Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. T. Eoin West is with the Department of Medicine, Harborview Medical Center, University of Washington, Seattle, Washington, United States of America. Direk Limmathurotsakul and Sharon J. Peacock are with the Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Sharon J. Peacock is also with the Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom. Funding: ACC is supported by a Health Professional Research Fellowship from the Australian National Health and Medical Research Council. TEW is funded by National Institutes of Health grant U54AI057141. SJP is supported by the Wellcome Trust. The funding bodies played no role in the decision to submit the article or in its preparation. Competing Interests: The authors have declared that no competing interests exist. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||
Crit Care Med. 1992 Jun; 20(6):864-74.
[Crit Care Med. 1992]Crit Care Med. 2001 Jul; 29(7):1303-10.
[Crit Care Med. 2001]N Engl J Med. 2003 Apr 17; 348(16):1546-54.
[N Engl J Med. 2003]J Indian Med Assoc. 2007 Apr; 105(4):221.
[J Indian Med Assoc. 2007]Lancet. 2003 May 17; 361(9370):1715-22.
[Lancet. 2003]Chest. 2005 Nov; 128(5):3674-8.
[Chest. 2005]Clin Infect Dis. 2007 Aug 1; 45(3):308-14.
[Clin Infect Dis. 2007]Crit Care Med. 2008 Jan; 36(1):296-327.
[Crit Care Med. 2008]N Engl J Med. 2006 Oct 19; 355(16):1640-2.
[N Engl J Med. 2006]N Engl J Med. 2001 Nov 8; 345(19):1368-77.
[N Engl J Med. 2001]Crit Care Med. 2006 Jun; 34(6):1589-96.
[Crit Care Med. 2006]Lancet Infect Dis. 2003 Sep; 3(9):547-56.
[Lancet Infect Dis. 2003]Intensive Care Med. 2003 Apr; 29(4):530-8.
[Intensive Care Med. 2003]Am J Physiol. 1982 Jul; 243(1):R131-41.
[Am J Physiol. 1982]Am J Med. 1973 Apr; 54(4):421-32.
[Am J Med. 1973]N Engl J Med. 2001 Nov 8; 345(19):1368-77.
[N Engl J Med. 2001]Crit Care Med. 1983 Nov; 11(11):839-50.
[Crit Care Med. 1983]Crit Care Med. 2008 Jan; 36(1):296-327.
[Crit Care Med. 2008]N Engl J Med. 2004 May 27; 350(22):2247-56.
[N Engl J Med. 2004]J Burn Care Res. 2006 Nov-Dec; 27(6):819-25.
[J Burn Care Res. 2006]Pediatrics. 2002 Apr; 109(4):566-72.
[Pediatrics. 2002]Crit Care Med. 2004 Sep; 32(9):1928-48.
[Crit Care Med. 2004]Crit Care Med. 2008 Jan; 36(1):296-327.
[Crit Care Med. 2008]Ann Intern Med. 1990 Aug 1; 113(3):227-42.
[Ann Intern Med. 1990]Crit Care Med. 2004 Sep; 32(9):1928-48.
[Crit Care Med. 2004]Padiatr Padol. 1979; 14(2):211-6.
[Padiatr Padol. 1979]N Engl J Med. 2001 Nov 8; 345(19):1368-77.
[N Engl J Med. 2001]Crit Care Med. 2007 Nov; 35(11):2525-32.
[Crit Care Med. 2007]Crit Care Med. 2006 Jun; 34(6):1589-96.
[Crit Care Med. 2006]Am J Med. 2003 Nov; 115(7):529-35.
[Am J Med. 2003]N Engl J Med. 2005 Jan 6; 352(1):39-47.
[N Engl J Med. 2005]Am J Trop Med Hyg. 2004 Jun; 70(6):670-5.
[Am J Trop Med Hyg. 2004]J Infect Dis. 1989 May; 159(5):890-9.
[J Infect Dis. 1989]Ann Trop Med Parasitol. 2006 Jun; 100(4):363-70.
[Ann Trop Med Parasitol. 2006]Am J Trop Med Hyg. 2006 Nov; 75(5):978-85.
[Am J Trop Med Hyg. 2006]Emerg Infect Dis. 2001 Mar-Apr; 7(2):302-5.
[Emerg Infect Dis. 2001]Clin Infect Dis. 2006 Feb 1; 42(3):377-82.
[Clin Infect Dis. 2006]Lancet. 1989 Sep 23; 2(8665):697-701.
[Lancet. 1989]Antimicrob Agents Chemother. 2007 Mar; 51(3):819-25.
[Antimicrob Agents Chemother. 2007]Southeast Asian J Trop Med Public Health. 1992 Jun; 23(2):189-94.
[Southeast Asian J Trop Med Public Health. 1992]J Antimicrob Chemother. 1988 Jan; 21(1):125-31.
[J Antimicrob Chemother. 1988]Crit Care Med. 2008 Jan; 36(1):296-327.
[Crit Care Med. 2008]Clin Infect Dis. 2007 Aug 1; 45(3):308-14.
[Clin Infect Dis. 2007]N Engl J Med. 2002 Sep 19; 347(12):895-902.
[N Engl J Med. 2002]N Engl J Med. 2001 Nov 8; 345(19):1368-77.
[N Engl J Med. 2001]Bull World Health Organ. 1997; 75 Suppl 1():7-24.
[Bull World Health Organ. 1997]Semin Thromb Hemost. 1998; 24(4):367-79.
[Semin Thromb Hemost. 1998]J Med Assoc Thai. 2007 Jul; 90(7):1342-7.
[J Med Assoc Thai. 2007]J Thromb Haemost. 2007 Jul; 5 Suppl 1():68-72.
[J Thromb Haemost. 2007]Am J Surg. 1982 Jul; 144(1):124-30.
[Am J Surg. 1982]Am J Respir Crit Care Med. 1995 Feb; 151(2 Pt 1):293-301.
[Am J Respir Crit Care Med. 1995]Clin Infect Dis. 2007 Aug 1; 45(3):308-14.
[Clin Infect Dis. 2007]Epidemiol Infect. 2006 Apr; 134(2):315-22.
[Epidemiol Infect. 2006]Surg Clin North Am. 2006 Dec; 86(6):1409-29.
[Surg Clin North Am. 2006]N Engl J Med. 2002 Sep 19; 347(12):895-902.
[N Engl J Med. 2002]Clin Infect Dis. 2007 Aug 1; 45(3):308-14.
[Clin Infect Dis. 2007]PLoS Clin Trials. 2007 Feb 9; 2(2):e2.
[PLoS Clin Trials. 2007]Ann Trop Med Parasitol. 2006 Mar; 100(2):95-108.
[Ann Trop Med Parasitol. 2006]Clin Infect Dis. 2004 Jan 1; 38(1):32-7.
[Clin Infect Dis. 2004]Clin Infect Dis. 2007 Aug 1; 45(3):308-14.
[Clin Infect Dis. 2007]Pediatr Infect Dis J. 1988 Aug; 7(8):598-600.
[Pediatr Infect Dis J. 1988]N Engl J Med. 2008 Jan 10; 358(2):111-24.
[N Engl J Med. 2008]JAMA. 2002 Aug 21; 288(7):862-71.
[JAMA. 2002]Bull World Health Organ. 1997; 75 Suppl 1():7-24.
[Bull World Health Organ. 1997]Ann Trop Paediatr. 1987 Dec; 7(4):282-6.
[Ann Trop Paediatr. 1987]Health Policy. 1999 Jun; 47(3):207-23.
[Health Policy. 1999]Crit Care Clin. 2006 Jul; 22(3):433-8, viii.
[Crit Care Clin. 2006]Emerg Infect Dis. 2002 Dec; 8(12):1455-9.
[Emerg Infect Dis. 2002]Trans R Soc Trop Med Hyg. 1998 Nov-Dec; 92(6):601-6.
[Trans R Soc Trop Med Hyg. 1998]Epidemiol Infect. 2008 Jan; 136(1):73-9.
[Epidemiol Infect. 2008]Am J Trop Med Hyg. 2003 Dec; 69(6):634-40.
[Am J Trop Med Hyg. 2003]